Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase 1 Completed
16 enrolled
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase 1 Terminated
2 enrolled 6 charts
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase 1 Terminated
8 enrolled
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
Phase 1 Completed
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Phase 1 Completed
34 enrolled
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
7 enrolled
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Phase 1 Completed
44 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
27 enrolled
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
20 enrolled
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
24 enrolled
Flavopiridol in Treating Patients With Refractory Cancer
Phase 1 Completed
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase 1 Completed
30 enrolled
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Terminated
22 enrolled
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Terminated
40 enrolled
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Phase 1 Completed
15 enrolled
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
Phase 1 Completed
34 enrolled
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma
Phase 1 Completed
17 enrolled
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
BCX-1777 in Treating Patients With Refractory Cancer
Phase 1 Completed
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase 1 Terminated
36 enrolled
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
55 enrolled
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
Phase 1 Completed
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
Phase 1 Completed
40 enrolled
BMS-247550 in Treating Patients With Advanced Cancers
Phase 1 Completed
54 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1 Completed
60 enrolled
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
3 enrolled
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
45 enrolled
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
18 enrolled
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
Phase 1 Completed
70 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
Phase 1 Completed
40 enrolled
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
Phase 1 Completed
7 enrolled
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase 1 Terminated
30 enrolled